Nektar Therapeutics
NKTR
$0.8968
$0.08149.98%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 19.15% | -2.43% | 73.14% | 29.50% | 22.37% |
| Total Depreciation and Amortization | -41.42% | -32.64% | -30.19% | -48.08% | -36.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -270.54% | -64.68% | -107.12% | -127.48% | 318.06% |
| Change in Net Operating Assets | 133.83% | 215.42% | -167.62% | 41.35% | 88.36% |
| Cash from Operations | -4.30% | 26.82% | 7.76% | 18.47% | 49.18% |
| Capital Expenditure | -1,918.18% | -14.81% | 63.74% | 53.71% | 81.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15.25% | -32.23% | -52.68% | -35.53% | -50.53% |
| Cash from Investing | -18.25% | -32.53% | -52.56% | -56.56% | -49.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 5.56% | -- | -88.35% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 5.56% | -- | -88.35% | -- |
| Foreign Exchange rate Adjustments | 71.43% | -100.93% | -117.78% | -85.45% | 66.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.72% | 21.07% | 218.57% | -69.09% | -49.69% |
